Authors:
MAKAR AP
BAEKELANDT M
TROPE CG
KRISTENSEN GB
Citation: Ap. Makar et al., THE PROGNOSTIC-SIGNIFICANCE OF RESIDUAL DISEASE, FIGO SUBSTAGE, TUMORHISTOLOGY, AND GRADE IN PATIENTS WITH FIGO STAGE-III OVARIAN-CANCER, Gynecologic oncology, 56(2), 1995, pp. 175-180
Citation: Ap. Makar, PROGNOSTIC STUDIES IN CANCER OF THE OVARY AND FALLOPIAN-TUBE WITH EMPHASIS ON THE CA-125 ANTIGEN AND C-ERBB-2 ONCOGENE, Acta obstetricia et gynecologica Scandinavica, 74(3), 1995, pp. 238-240
Authors:
MAKAR AP
HOLM R
KRISTENSEN GB
NESLAND JM
TROPE CG
Citation: Ap. Makar et al., THE EXPRESSION OF C-ERBB-2 (HER-2 NEU) ONCOGENE IN INVASIVE OVARIAN MALIGNANCIES/, International journal of gynecological cancer, 4(3), 1994, pp. 194-199
Authors:
MAKAR AP
KAERN J
KRISTENSEN GB
VERGOTE I
BORMER OP
TROPE CG
Citation: Ap. Makar et al., EVALUATION OF SERUM CA-125 LEVEL AS A TUMOR-MARKER IN BORDERLINE TUMORS OF THE OVARY, International journal of gynecological cancer, 3(5), 1993, pp. 299-303
Authors:
MAKAR AP
KRISTENSEN GB
BORMER OP
TROPE CG
Citation: Ap. Makar et al., IS SERUM CA-125 AT THE TIME OF RELAPSE A PROGNOSTIC INDICATOR FOR FURTHER SURVIVAL PROGNOSIS IN PATIENTS WITH OVARIAN-CANCER, Gynecologic oncology, 49(1), 1993, pp. 3-7
Authors:
MAKAR AP
KRISTENSEN GB
BORMER OP
TROPE CG
Citation: Ap. Makar et al., SERUM CA-125 LEVEL ALLOWS EARLY IDENTIFICATION OF NONRESPONDERS DURING INDUCTION CHEMOTHERAPY, Gynecologic oncology, 49(1), 1993, pp. 73-79